William Shomali, MD
Hematology · Stanford, CANPI 1407113871
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $20,612 of the $26,377 with a category attached, or 78.1%. Incyte Corporation accounts for 89.1% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2021 at $12,546 and has fallen 84.4% since, to $1,962 in 2025.
Across 7 payments — averaging $3768.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$24K
- Blueprint Medicines Corporation$3K
- Bristol Myers Squibb$22
Across 675 payments — averaging $2908.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$1.5M
- Blueprint Medicines Corporation$402K
- Sanofi US Services Inc.$31K
What the payments were for
- Consulting fees$20,61278%
- Speaking & faculty fees$5,74222%
- Food & beverage$220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 5 | $23,508 |
| Blueprint Medicines Corporation | 1 | $2,846 |
| Bristol Myers Squibb | 1 | $22 |
How this compares
$26,377 in reported general payments places this provider in the 65th percentile of 178 hematology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxyurea | 25 | $238 |
| Acyclovir | 14 | $164 |
Paid to pharmacies, not to this prescriber.
Other hematology in Stanford
- Everett MeyerStanford$2.1M
- Deepu MadduriStanford$348K
- Surbhi SidanaStanford$170K
- Michaela LiedtkeStanford$112K
- Sydney LuStanford$110K
- Saurabh DahiyaStanford$94K
- David MiklosStanford$90K
- Lori MufflyStanford$87K
- Ravindra MajetiStanford$58K
- Robert NegrinStanford$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.